Coronary Thrombolysis with TissueType Plasminogen Activator

Treatment of experimental suprachoroidal hemorrhage with intravenous tissue plasminogen activator

Suprachoroidal hemorrhages were created in 15 albino rabbit eyes by injecting 0.1 cc of autologous blood into the suprachoroidal space. One day later, 10 of these eyes were treated with intravenous tissue plasminogen activator (TPA). Doses of 1 mg per kg were given to each rabbit over 2 to 3 hours by intravenous infusion. Five eyes served as control. The rate of clearance of hemorrhage was compared in the two groups. Average day of clearance was 14 days for the treated group, and 20.2 for the untreated control group. In this study, TPA given intravenously appears to accelerate the clearance of suprachoroidal hemorrhage.

Myocardial infarction: current management strategies

Coronary artery disease is a common malady in industrialized societies. The end stage of this progressive disorder frequently results in myocardial infarction (MI), now known to be due to acute thrombosis of a narrowed coronary artery. In the past, supportive care was all that could be offered to patients suffering MI. But the new therapeutic modalities of thrombolysis and transluminal coronary angioplasty now offer a means of limiting the damage caused by coronary stenosis and thrombosis in many cases. This article reviews conventional, recently introduced, and possible future treatment strategies to manage coronary obstruction. Current concepts of handling the patient suffering a suspected acute coronary thrombosis in the office setting are presented as well.